SCHEMBL4604518

SCHEMBL4604518

Nc1c(Sc2ccccc2)cc(C(F)(F)F)cc1C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.46
MAPT P10636 2/20 0.46
HTT P42858 2/20 0.46
KDM4E B2RXH2 2/20 0.45
ALDH1A1 P00352 2/20 0.45
HPGD P15428 1/20 0.45
HSD17B10 Q99714 1/20 0.45
SIRT1 Q96EB6 1/20 0.43
DDR1 Q08345 1/20 0.41
ADORA2A P29274 1/20 0.40
KCNQ3 O43525 1/20 0.40
KCNQ2 O43526 1/20 0.40
P2RX1 P51575 2/20 0.39
TAS2R14 Q9NYV8 6/20 0.39
RXRA P19793 1/20 0.38
RXRB P28702 1/20 0.38
TDP1 Q9NUW8 1/20 0.37
ADRA2B P18089 1/20 0.36
ADRA2C P18825 1/20 0.36
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11709910 0.81 KCNQ3 (0.56) LMNAMAPTHTTKDM4EALDH1A1
SCHEMBL8108703 0.81 ALDH1A1 (0.53) LMNAMAPTHTTKDM4EALDH1A1
SCHEMBL4603436 0.79 MAPT (0.57) LMNAMAPTHTTALDH1A1HPGD
Methylene Chloride SCHEMBL8211467 0.76 ALDH1A1 (0.48) LMNAMAPTHTTKDM4EALDH1A1
SCHEMBL1202626 0.73 KDM4E (0.62) MAPTKDM4EALDH1A1HPGDHSD17B10
SCHEMBL8533504 0.72 MAPT (0.56) LMNAMAPTHTTKDM4EALDH1A1
SCHEMBL18085711 0.72 KDM4E (0.61) KDM4EALDH1A1HPGDHSD17B10TAS2R14
SCHEMBL30034276 0.72 KDM4E (0.51) KDM4EALDH1A1HPGDHSD17B10P2RX1
SCHEMBL16676482 0.70 KDM4E (0.50) KDM4EALDH1A1HPGDHSD17B10P2RX1
SCHEMBL16529671 0.70 KDM4E (0.50) MAPTKDM4EALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1720825-B1 ANTHRANILIC ACID DERIVATIVES, METHODS FOR THEIR PREPARATION AND USE AS DHODH INHIBITORS ACTIVE BIOTECH AB (SE) 2008-07-09 EP disclosed
EP-1720825-A1 NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF Active Biotech AB (SE) 2006-11-15 EP disclosed
US-7074831-B2 Compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB (SE) 2006-07-11 US disclosed
US-20050187297-A1 New compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB (SE) 2005-08-25 US disclosed
WO-2005075410-A1 NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF ACTIVE BIOTECH AB (SE) 2005-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187297-A1 New compounds, methods for their preparation and use thereof MALT1, TPMT, FUCA1 LMNA 4153/4885MAPT 3698/4885HTT 3670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.